Campbell & Co Investment Adviser’s Dyne Therapeutics DYN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64,517	Closed	-$816K	–	1197
2025 Q3	$816K	Buy	+64,517	New	+$736K	0.06%	503
2024 Q4	–	Sell	-16,956	Closed	-$609K	–	1123
2024 Q3	$609K	Sell	16,956 -8,011	-32%	-$319K	0.05%	629
2024 Q2	$881K	Sell	24,967 -12,801	-34%	-$372K	0.07%	417
2024 Q1	$1.07M	Buy	37,768 +19,268	+104%	+$436K	0.09%	365
2023 Q4	$246K	Buy	+18,500	New	+$181K	0.02%	979

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Campbell & Co Investment Adviser's DYN Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 64,517 shares — an estimated $816K sold.

Campbell & Co Investment Adviser first reported a position in DYN in Q4 2023 and held it in 5 quarters. The position peaked at $1.07M in Q1 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 64,517 Dyne Therapeutics shares in Q4 2025, an estimated $816K.
Campbell & Co Investment Adviser first reported a position in Dyne Therapeutics in Q4 2023 and held it in 5 quarters.
Campbell & Co Investment Adviser's Dyne Therapeutics position peaked at $1.07M in Q1 2024.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.